AstraZeneca and Ionis report major trial failure for heart disease drug Wainua
AstraZeneca and Ionis Pharmaceuticals said this week that a major clinical trial of their heart disease drug Wainua did not meet its main goals, a setback for a treatment aimed at a specific and serious inherited heart condition in a market that has become increasingly crowded with competing therapies.
Wainua, known chemically as eplontersen, is designed to treat transthyretin amyloid cardiomyopathy, a progressive condition in which a misfolded protein called transthyretin builds up as amyloid deposits in the heart muscle, gradually stiffening it and impairing its ability to pump blood effectively. The disease can be inherited or can develop later in life without a clear genetic cause.
The drug had already secured approval for a related condition, transthyretin amyloid polyneuropathy, which damages nerves rather than the heart. Regulators and drugmakers had hoped success in the newer trial would extend Wainua's use to the substantially larger population of patients whose amyloid disease primarily affects the heart.
Details of exactly which trial endpoints were missed were not fully disclosed, but the companies described the outcome as a major trial failure rather than a narrow miss, signaling a significant setback for the cardiac indication specifically, even as the drug's approved use for nerve damage remains unaffected by the result.
The treatment landscape for transthyretin amyloid cardiomyopathy has shifted rapidly in recent years, moving from a rare disease with almost no treatment options a decade ago to a competitive field with several approved and experimental drugs using different mechanisms, including some that stabilize the transthyretin protein rather than reducing its production, as Wainua does.
Analysts have said that any drug entering this market now faces a much higher bar for clinical evidence than earlier treatments did, since physicians and payers can compare new options directly against therapies that have already demonstrated clear benefits for patients in large trials.
AstraZeneca and Ionis said they are continuing to evaluate the full trial data and have not yet outlined next steps for Wainua's development specifically in the cardiac indication. The companies emphasized that the drug remains an approved treatment option for the nerve-damage form of the disease.
The setback comes amid a broader wave of high-profile trial disappointments across the pharmaceutical industry this year, a reminder that even therapies built on well-understood biology can fail to translate into measurable clinical benefit once tested in large, controlled patient populations.
For patients living with transthyretin amyloid cardiomyopathy, the news means one fewer near-term option in what remains a serious and often under-diagnosed condition, though doctors note that several alternative treatments are already approved and available for eligible patients.
Industry analysts say the result is likely to prompt renewed scrutiny of the various treatment mechanisms being pursued for the disease, and could influence how competitors position their own late-stage trials currently underway in the same crowded field.
Read next
DNA on a chip: how Harvard's silicon device writes genetic code with electricity
Harvard scientists have built a silicon chip that can write dozens of DNA sequences at once using electricity and water-based enzymes, offering a cleaner alternative to conventional DNA manufacturing. The breakthrough could eventually enable portable DNA-writing devices and even large-scale DNA-based data storage.
What are 'forever chemicals'? Inside New York's lawsuit against 3M and DuPont
New York has sued 3M, DuPont and other manufacturers, accusing them of hiding for decades the health and environmental risks of PFAS, chemicals nicknamed 'forever chemicals' because they barely break down in the environment or the human body. Here is what the chemicals are and why regulators are targeting them.
What is cyclosporiasis, the parasitic illness causing 'explosive' diarrhea in the US?
Cyclosporiasis, a parasitic illness that causes severe, watery diarrhea, has surged across parts of the United States, with an outbreak of nearly 1,000 cases reported in Michigan alone. Health officials say the illness is rarely life-threatening but can cause weeks of debilitating symptoms if untreated.
Identical twins Nancy and Margo: the womb surgery that saved them from a rare condition
Identical twins Nancy and Margo have been born healthy after doctors treated them in the womb for a rare, life-threatening pregnancy condition as part of a world-first medical trial. The procedure targets a dangerous imbalance in blood flow that can develop between twins who share a placenta.
UK vape crackdown: how flavour names and packaging rules would change
The UK government is consulting on rules that would strip vapes of enticing flavour names and bright packaging, aiming to stop products being marketed to children. About one in five UK teenagers has tried vaping, officials say, prompting calls to bring e-cigarette rules closer to tobacco law.